Franz Schnetzinger

Franz Schnetzinger is an experienced professional in quality control and analytical development, currently serving as Head of PAD & QC at AAVantgarde Bio since July 2024. With a strong focus on AAV programs, Franz has also contributed as a member of the ATMP working group for The British Pharmacopoeia since March 2020. Previous roles include CMC Technology Lead at CEPI, Executive Director of Quality Control and Analytical Development at Novartis Gene Therapies, and VP of Quality Control and CMC Analytical Development at Gyroscope Therapeutics. Franz's extensive background in analytical strategy development spans several significant positions at leading companies, including GSK and Baxter BioScience, showcasing a robust expertise in the biotechnology sector. Education includes a Master of Science in Analytical Biotechnology from Cranfield University.